VP & Head of Induced Proximity Platform, @Amgen | Scientist | Father
Joined January 2014
- Tweets 766
- Following 364
- Followers 2,205
- Likes 2,030
105 Photos and videos
Pinned Tweet
21 Aug 2025
What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. science.org/doi/10.1126/scie…
#mycompnay
9
32
141
25,068
Ryan Potts retweeted
Apr 27
Excited to share our discovery of a new programmable RNA-guided DNA-targeting system hiding inside bacteriophages that predates CRISPR.
We call it VIPR (Viral Interference Programmable Repeat), and it uses an entirely new logic to find its targets.
Thread link below.
26
353
1,257
241,067
Ryan Potts retweeted
Mar 28
What if a small molecule could activate a transcription factor program in one cell type and destroy the same pathway in another? In our new preprint, we describe one such story on bifunctional molecules that toggle between transactivation and repression.
7
87
463
60,240
Ryan Potts retweeted
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small Molecules biorxiv.org/content/10.64898… #biorxiv_biochem
2
7
630
Ryan Potts retweeted
Functional inactivation of the telomerase chaperone TCAB1 primes cells for the activation of ALT in osteosarcoma biorxiv.org/content/10.64898… #biorxiv_cancer
1
3
360
Ryan Potts retweeted
14 Dec 2025
Selinexor is an allosteric degrader: it stabilizes XPO1/CRM1 to expose a cryptic ASB8 E3 ligase site, triggering ubiquitination. Led by Casey Wing, Joyce Fung & Bert Kwanten. #TargetedDegradation #Allostery
nature.com/articles/s41589-0…
1
2
13
1,373
Ryan Potts retweeted
3 Dec 2025
Mapping the latent CRBN-molecular glue degrader interactome biorxiv.org/content/10.64898… #biorxiv_molbio
2
11
1,916
Ryan Potts retweeted
30 Nov 2025
Orthosteric Molecular Glue Inhibits COP9 Signalosome with Substrate-Dependent Potency biorxiv.org/content/10.1101/… #biorxiv_molbio
1
3
602
Ryan Potts retweeted
20 Sep 2025
Thrilled to share that I have joined @Amgen
as the inaugural Amgen Science Fellow. I look forward to partnering with colleagues to design next-gen therapeutic by integrating AI/ML with high throughput synthetic biology platforms.
linkedin.com/posts/drhoward-…
1
2
40
3,883
Ryan Potts retweeted
7 Sep 2025
Legend David Baltimore died yesterday. He understood the way things should work: "the real contribution of @MIT is that it doesn't take itself too seriously. It takes ideas seriously, but the people are relatively informal. They are not self-aggrandizing the way academics can be.
13
128
620
106,285
Ryan Potts retweeted
28 Aug 2025
Thrilled to share our work to find natural products that inhibit β-catenin! This is the result of an amazing collaboration with @theNCI Natural Products Branch and shows the power of 'up' assays to find new and interesting molecules! biorxiv.org/content/10.1101/…
8
29
2,635
Ryan Potts retweeted
27 Aug 2025
A new #ScienceReview looks at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.”
Learn more: scim.ag/4lAiKmF
ALT LOCKTACs comprise a subset of proximity drugs that stabilize naturally existing complexes. (A) Categories of proximity-based drugs. (B) Mechanism of PROTAC drugs. (C) LOCKTAC acting within a protein-protein interface. (D) LOCKTAC acting adjacent to a protein-protein interface. (E) Heterobifunctional LOCKTAC that does not bind at protein-protein interface. (F) Allosteric drugs induce conformational changes at a distance and are not LOCKTACs.
7
56
257
35,375
Ryan Potts retweeted
22 Aug 2025
Great to see our two in-house developed kinetic stabilizers, Tolcapone and PITB, against transthyretin amyloidoses cited as examples of an emerging therapeutic class: LOCKTACS. science.org/doi/10.1126/scie…
4
14
800
Ryan Potts retweeted
22 Aug 2025
Talking of @amgen they also have cool LYMTACs: chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization & degradation nature.com/articles/s41467-0…
1
6
19
2,607
Ryan Potts retweeted
22 Aug 2025
Degradation without E3s?
Cool approach here - molecules that drag membrane proteins into lysosomes for degradation
Might help get around KRASi resistance
10 Sep 2024
🚨New @biorxivpreprint from the @Amgen Induced Proximity group. Here we introduce LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation. 🧵 biorxiv.org/content/10.1101/…
1
6
874
Amgen’s LOCKTAC molecular glues are changing how we target disease.
🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.
Read more about how Amgen is working to innovate in this space.
5
5
19
4,777
21 Aug 2025
Check out how we repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @nalawansha and team! #mycompany
nature.com/articles/s41467-0…
10 Sep 2024
🚨New @biorxivpreprint from the @Amgen Induced Proximity group. Here we introduce LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation. 🧵 biorxiv.org/content/10.1101/…
5
32
4,571
Ryan Potts retweeted
18 Aug 2025
From decoding the genome’s “dark matter” to designing next-gen medicines, @HowardYChang is the ideal leader for @Amgen Research.
Tackling the toughest problems in therapeutic science requires deep insights into human biology, creative new technologies in molecular biology, comfort in computation, and a wiring for collaboration. Can think of nobody better to lead therapeutics discovery. Let's gooooo! #MyCompany
Read more: nature.com/articles/d41573-0…
3
3
62
5,007
Ryan Potts retweeted
4 Aug 2025
The passing Of Dave Mangelsdorf is a terrible loss for his family, friends and the science world. Davo will never be forgotten. 😢 chapelgazette.cfd/david-mang…
7
27
129
14,274